Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 14, 2019* First and only vaccine approved in the U.S. for repeat vaccination 8 years or more after the first vaccination to help protect against tetanus, diphtheria and pertussis, offering flexibility for health care providers to help manage their immunization schedules(2)
-
Jan 9, 2019-HERCULES Phase 3 trial met its primary endpoint, demonstrating that treatment with Cablivi resulted in a significantly faster time to platelet count response in patients with acquired thrombotic thrombocytopenic purpura (aTTP) when administered in conjunction with plasma exchange and immunosuppression
-
Jan 3, 2019Provention is currently developing PRV-101 as a vaccine for acute coxsackie infection and to potentially prevent the onset of T1D
-
Nov 11, 2018* Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL
-
Nov 8, 2018Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m., ET
-
Nov 7, 2018* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)